Xeltis technology enables cardiovascular regeneration in high blood pressure, preclinical data showed at ISACB
Six-month preclinical data from trials of a Xeltis bioabsorbable aortic conduit were presented today at the 15th Biennial Meeting of the International Society for Applied Cardiovascular Biology (ISACB) in Banff, Canada. The data presented by Professor Schoen from the Brigham and Women’s Hospital and Harvard Medical School, Boston, showed that a Xeltis bioabsorbable aortic conduit enabled Endogenous Tissue Restoration (ETR) in the systemic circulation, the part of the cardiovascular system flowing via the aorta throughout the body.
Systemic circulation is characterized by higher blood pressure than pulmonary circulation, a loop through heart and lungs. Xeltis bioabsorbable cardiovascular technology has already been proven to effectively enable Endogenous Tissue Restoration (ETR) in pulmonary circulation.
“The data presented by Professor Schoen represented a fundamental starting point to expand the applications of Xeltis’ cardiovascular technology beyond the low-blood pressure circuit” – explained CEO Laurent Grandidier. “They showed the potential of bioabsorbable heart valves to become a new standard of care not only in pulmonary valve replacement but also in aortic valve replacement, a treatment needed by a much larger number of adult patients worldwide.”